Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 122
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B04F9DB3D93EN
Leaflet:

Download PDF Leaflet

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape.

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bipolar Disorder (Manic Depression) Overview
Therapeutics Development
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bipolar Disorder (Manic Depression) - Products under Development by Companies
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development
Aequus Pharmaceuticals Inc.
Amorsa Therapeutics Inc.
AstraZeneca Plc
Biogen Inc
Delpor, Inc.
Intas Pharmaceuticals Ltd.
Intra-Cellular Therapies, Inc.
Johnson & Johnson
KemPharm, Inc.
Mapi Pharma Ltd.
Navya Biologicals Pvt Ltd
Neurocrine Biosciences Inc
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Reviva Pharmaceuticals Inc.
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co Ltd
Zogenix, Inc.
Zysis Limited
Bipolar Disorder (Manic Depression) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cycloserine + lurasidone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-1407 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-2803 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cenobamate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNV-1061436 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-18038683 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paliperidone palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGW-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
quetiapine fumarate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-PSY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bipolar Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cancer and Neurodegenerative Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Bipolar Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziprasidone mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bipolar Disorder (Manic Depression) - Dormant Projects
Bipolar Disorder (Manic Depression) - Discontinued Products
Bipolar Disorder (Manic Depression) - Product Development Milestones
Featured News & Press Releases
Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia
Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office
Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan
Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition
May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression
May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association
Feb 25, 2016: Intra-Cellular Therapies Provides Product Update
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression
Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder
Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 122

LIST OF TABLES

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Biogen Inc, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences Inc, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2016
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2016
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2016
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H2 2016
Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2016 107

LIST OF FIGURES

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: